Serine/threonine phosphorylation may be an important target of certain chemotherapeutic drugs which recognize the activated proteins. This meeting report and mini-review will discuss the interactions of serine/threonine kinases with signal transduction and apoptotic molecules and how some of these pathways can be controlled by chemotherapeutic drugs. Leukemia (2000) 14, 9-21.
Introduction
In the early 1990s, the identification of the Jak tyrosine kinases and their roles in cytokine signal transduction were elucidated. [1] [2] [3] [4] [5] [6] A relatively simple signal transduction model arose which included a cytokine/interferon receptor with associated Jak kinases and downstream STAT transcription factors. The Jak kinases would be activated upon ligand-induced receptor oligomerization. They would phosphorylate STAT molecules on tyrosine residues, which would allow the STAT molecules to dimerize, promote nuclear translocation, increase their DNA binding activity and regulate gene expression. Many cytokine receptors were shown to utilize this basic signal transduction model (eg IL-2R, IL-3R, IL-5R, Epo-R, GM-CSFR and others). As with most hypotheses, however, this simple model was incomplete, and ignored the branched nodal nature of intracellular signaling cascades. Studies of the stem cell factor (SCF) induced biological activity illustrate well the downstream complexity and requirement for serine/threonine phosphorylation to integrate cytokine-induced tyrosine phosphorylation with the downstream signaling cascades regulating differentiation and cell proliferation. SCF can be synthesized as membrane-bound or soluble forms. However, the differences these two forms have on signal transduction and biological responses are not well understood. SCF transduces its effects through the c-Kit receptor, which has intrinsic tyrosine kinase activity. Receptors such as c-Kit which have tyrosine kinase activity recruit signaling molecules which bind the autophosphorylated receptors or their tyrosine phosphorylated substrates. This binding occurs via a Src homology 2 domain (SH2, a protein domain related to phosphotyrosine binding domain of Src).
Dr David Williams (Howard Hughes Medical Institute, Indiana University, Indianapolis, IN, USA) has used specific knockout and transgenic mice to examine the differential ability of membrane-bound and soluble forms of SCF to induce downstream signal pathways. 7, 8 Dr Williams' work indicates that activation of extracellular regulated kinases 1 and 2 (ERK1 and ERK2, also known as p42 MAPK and p44 MAPK ), p38 MAPK and phosphatidylinositol 3-kinase (PI3K) occurs in response to bone marrow-derived stromal cells expressing the membrane-restricted but not the soluble form of SCF. 8 Moreover, differences were also observed in the development of the two different types of mice. Introduction of the membranerestricted form of murine SCF into Steel-Dickie mice, which contain a mutation in the gene encoding SCF, resulted in a significant improvement in the production of red blood cells and a decrease in bone marrow hypoplasia and runting. 2 However, when the full-length soluble form of SCF was introduced into these mutant mice, no improvement was observed. Thus the proliferative and differentiative effects induced by SCF may involve tyrosine and serine/threonine kinases. These data demonstrate that, the two different forms of SCF have distinct biological functions. An overview of some of the effects of cytokines on signal transduction pathways is presented in Figure 1 . In the following discussion, we will consider the role of the most important serine/threonine kin-
Figure 1
Cytokine regulation of signal transduction and apoptotic molecules. The effects of cytokines and interferons on signal transduction and apoptotic molecules are indicated. Some of the effects and sites of serine/threonine and tyrosine kinases are highlighted in yellow. A red 'P' in a white circle indicates phosphorylated serine/threonine residues on proteins. A black 'P' in a white circle indicates phosphorylated tyrosine residues. Cytokine receptors are shown in black, cytokines are shown in red. Solid lines indicate the pathways initiated after receptor ligation. The intermediary signal transducing molecules are indicated in orange. The kinases are indicated in green. Transcription factors are indicated in blue. Pro-apoptotic proteins are indicated in brown, as is the Shp2 phosphatase. Anti-apoptotic molecules are indicated in maroon. Chaperonin molecules are indicated in black. Phospholipid (PL) and diacyl glycerol (DAG) are indicated in orange. Skull and cross bones indicates that apoptosis is induced. Skull and cross bones with a red 'X' through it indicates that apoptosis is prevented.
ases that participate in cytokine signaling and the biological consequences of their activation and dysregulation.
Phosphatidylinositol 3-kinase (PI3K) and Akt/protein kinase B (PKB)
The stimulation of appropriate target cells by cytokines also leads to the rapid activation of PI3K. [9] [10] [11] [12] [13] [14] P13Ks can catalyze the conversion of phosphatidylinositol (PtdIns), PtdIns(4)P and PtdIns(4,5)P 2 into PtdIns(3)P, PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 .
14 The lipid products of PI3K serve to localize and activate additional downstream signal transduction molecules (Rac, protein kinase B (PKB also known as Akt)) in the vicinity of the cell membrane. These PI3K lipid products vary in terms of their abundancy in cells. For example, PtdIns(3)P is always present in cells and does not increase upon cellular stimulation. In contrast, the levels of PtdIns(3,4) P 2 and PtdIns(3,4,5) P 3 are present only in very low levels in resting cells and increase dramatically upon stimulation. 14 PI3K is a heterodimeric protein consisting of an 85-kDa regulatory subunit, which contains SH2, and SH3 domains (Src homology region 3, a protein domain related to a proline rich binding domain found in Src), and a 110 kDa catalytic subunit.
9-17 PI3K belongs to a multi-gene family, which has been divided into three classes based on their lipid substrate specificities, the presence of certain key structural motifs and perhaps by the mechanisms by which the proteins are regulated. There are three different isoforms of p110 expressed in hematopoietic cells (␣, ␤, ␦) with the ␦ isoform appearing to be restricted to only hematopoietic cells. [9] [10] [11] [12] [13] However, the roles that these different isoforms have in cytokine signaling remain to be fully elucidated. IL-3-induced tyrosine phosphorylation of the IL-3 receptor ␤-chain creates a docking site at tyrosine 612 (Y612) for the tyrosine phosphatase SHP2.
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SHP2 can then associate with the adaptor protein, which subsequently interacts with the SH2 domain of the p85 subunit of PI3K. 10 The adaptor protein can also bind phosphorylated tyrosine residues on Src family kinases, linking PI3K catalytic subunits to tyrosine kinase regulated signal transduction path-ways.
14 This may serve to localize PI3K to the cellular membrane, which is rich in lipid substrates. In this context, PI3Ks may be able to interact with the Ras GDP/GTP exchange proteins in a GTP-dependent fashion. Ras has been shown to function either upstream or downstream of PI3Ks depending upon the particular stimulus. 14 Once the p85 PI3K subunit is phosphorylated, activation of the p110 catalytic subunit occurs that in turn activates the downstream targets p70 ribosomal S6 kinase (p70S6K), PKB, also known as Akt, and NF-B. [18] [19] [20] [21] The drugs wortmannin and Ly 294002 are specific inhibitors of PI3K. In addition, there also exist dominant negative mutants of p85 and antisense vectors. Rapamycin is an inhibitor of p70 S6 kinase activation. 15 Rapamycin inhibits p70S6 kinase by a protein referred to as target of rapamycin (TOR). These reagents allow the investigator the ability to determine the importance of this pathway in different physiological conditions. PKB is also a member of a multigene family. Currently three members of this family have been identified. The PKB family members all contain an amino-terminal pleckstrin homology (PH) domain, a catalytic domain and finally a carboxyl terminal domain which lacks homology with other proteins. 14, 16 Activation of PKB occurs in two phases, phosphorylation on serine/threonine residues and targeting to the lipid rich cell membrane by the N-terminal PH domain. 9 The PH domain may mediate binding to certain lipid activators. Phosphorylation of threonine 308 (T308 in the catalytic domain) and serine 473 (S473 in the carboxyl-terminal domain) results in the activation of PKB. T308 is phosphorylated by the PtdIns(3,4) P 2 (3,4,5)P 3 -dependent kinase (PDK1). The kinase which phosphorylates S473 is currently unknown, but is referred to as PDK2. Some evidence suggests that PDK2 may be the same as the integrin linked kinase (ILK). 17 High levels of PKB activity are only observed when both T308 and S473 are phosphorylated. 9, 18 The pro-apoptotic protein Bad may play an important role in determining whether a cell undergoes apoptosis. Korsmeyer and colleagues showed that phosphorylation of Bad at S112 and S136 resulted in its association with the cytosolic chaperonin protein 14-3-3, thereby sequestering it away from its binding partner Bcl-X L at the mitochondria. 19 Subsequent reports have suggested that one role of PI3K and PKB in preventing apoptosis is due to phosphorylation of Bad by PKB at S136. 20, 21 Dr Vincent Duronio (University of British Columbia, Vancouver, BC, Canada) discussed the state of phosphorylation of Bad in response to cytokines, and showed that phosphorylation of Bad could occur independently of PKB activation. 18 One explanation for the discrepancy is that the latter study examined phosphorylation of endogenous Bad protein by the endogenous PKB. Previous work examined tagged and overexpressed Bad, which was found to be phosphorylated by overexpressed PKB. Furthermore, in mouse MC/9 cells, Bad protein was not significantly phosphorylated at S136 in response to cytokines. Evidence was presented that phosphorylation at S112 was mediated by a MEK-dependent pathway, and this phosphorylation event was sufficient to regulate association of Bad with Bcl-X L . 22, 23 Furthermore, analysis of tryptic peptide maps of the endogenously phosphorylated Bad revealed at least one novel site of phosphorylation distinct from either S112 or S136. The relevance of cytokine-dependent PKB phosphorylation as a key player in prevention of apoptosis by some cytokines has been brought into question by studies from the laboratories of Duronio 18 ,24 and more recently Welham. 25, 26 The latter studies showed that cell survival could occur in the absence of Leukemia significant PKB activation, and utilized dominant negative forms of p85 to show the lack of involvement of the PI3K pathway in phosphorylation of Bad. In some cases, phosphorylation of Bad that was dependent upon PI3K could be observed, which suggests that this effect may be cell type dependent. In fact, it is possible that Bad phosphorylation at S112 could occur in a PI3K-dependent fashion if the PI3K pathway could contribute to activation of the MAPK pathway, as has been suggested from some studies. 27 Dr Duronio discussed results of studies showing that in MC/9 cells, MAPK activation was not dependent upon PI3K activation. 22 The main argument put forward was that while wortmannin could partially block activation of MAPK, as has been reported in numerous studies, concentrations of another PI3K inhibitor, Ly294002, that completely block PI3K had no effect on MAPK activation. In another recent study, 28 dominant negative forms of PI3K were used to show that selective inhibition of Raf isoforms may explain the ability of the PI3K pathway to affect MAPK in some cell systems, but not others. In summary, a variety of cytokines has been shown to activate the P13K pathway, but the exact relevance of that pathway, and particularly the phosphorylation of Bad, to cell survival may depend on the cellular context, as seems to be the case for interaction of the PI3K and MAPK pathways.
Another aspect of PKB regulation also involves dephosphorylation of PI3K-generated lipids by the SH2-containing inositol 5-phosphatase, or SHIP, protein. Studies using knockout mice lacking SHIP were done by the laboratories of Duronio and Krystal, whose laboratory was one of several that first cloned SHIP. 29 In bone marrow-derived mast cells from SHIP −/− mice, steel factor was found to cause a tremendous accumulation of PI(3,4,5)P 3 , that was as much as 100-fold higher than that in the SHIP +/+ cells, 30 while under the same conditions the SHIP −/− cells had lower levels of PI(3,4)P 2 . These results show that SHIP is the primary 5-phosphatase in hematopoietic cells. More recent studies were discussed that demonstrate the importance of both the PI(3,4,5)P 3 and PI(3,4)P 2 lipids in regulation of PKB activity and phosphorylation of PKB at the PDK1 and PDK2-dependent sites.
Raf/MEK/ERK activation by interferons, abrogation of cytokine dependency and prevention of apoptosis by activated Raf and MEK oncoproteins
Dr Andrew Larner (Cleveland Clinic Foundation, Cleveland, OH, USA) presented evidence indicating that in addition to being tyrosine phosphorylated, several STATs (STAT1␣, STAT3 and STAT4) are phosphorylated on a conserved serine residue. 31 This serine residue is a target of the serine/threonine kinase ERK. INF␣/␤ and INF␥ can activate Raf-1 and B-Raf which will in turn activate MEK and the downstream ERK1 and ERK2 kinases. [31] [32] [33] [34] [35] Serine phosphorylation of STAT1 and STAT3 is required for these STATs to maximally transactivate gene expression. Dr Larner described how ERK is activated in response to interferons (IFN). Using embryonic stem cells with a targeted deletion of B-Raf, Dr Larner was able to elucidate roles for B-Raf in the anti-viral and anti-proliferative effects of INF-␣. 34 Furthermore, transfection of Jurkat T cells with a kinase-inactive form of B-Raf significantly reduced the anti-proliferative effects of IFN-␣. These results demonstrate that an intricate cross-talk occurs between the Jak and Raf kinases in IFN signaling and that the Raf kinase pathway is essential for the biological effects of type 1 interferons.
Additional studies have shown intricate interactions occur between tyrosine kinase, serine/threonine kinases and STAT transcription factors, which can either, induce or repress their activities. [36] [37] [38] [39] It has been known for some time that v-Src expression can increase the Stat-3 binding activity in certain cells 36 suggesting that there can be interactions between a vSrc induced downstream activity (possibly ERK) and STAT. Moreover, it is now recognized that the Raf kinase can be activated by IFN␥ and oncostatin M. [31] [32] [33] [34] 39 Interestingly, activation of Raf by these factors requires Jak and STATs, but this activation is Ras-independent, reducing the possibility of the involvement of an autocrine loop. 32, 33, 39 An unanswered question is whether the physical sites of Raf-1 activation by Jak are the same as those involved in activation by Src family kinases (Y340 and Y341)? Studies performed by Dr Larner and colleagues have demonstrated an important link between the Jak and Raf signaling pathways.
Recently it was hypothesized that Src and not the Jak kinases were responsible for activating STAT in IL-3-induced proliferation. 38 Furthermore, certain phosphorylation events on STAT3 mediated by ERK2 have been shown to actually repress its activity. 39 Clearly protein phosphorylation of these transcription factors is a complex area with certain events being activating whereas others are inhibitory.
Downstream targets of Ras and certain protein kinase C (PKC) isoforms are the Raf kinases. The abilities of the different Raf kinases to abrogate the cytokine dependency of hematopoietic cells and induce downstream signal transduction pathways were discussed by Dr James McCubrey (East Carolina University, Greenville, NC, USA). 40 Abrogation of cytokine dependency is often linked to tumorigenesis. [41] [42] [43] Raf is a member of multi-gene family that consists of Raf-1, A-Raf and B-Raf. The roles of the individual Raf kinases in cytokinemediated signal transduction are beginning to be investigated. Raf-1 was the first Raf gene isolated and is fairly ubiquitously expressed. Raf is a serine/threonine kinase, which has been implicated as a downstream target of many cytokine receptors. Raf can pass the signal initiated from Ras, Src-like tyrosine kinases, PKCs, kinase suppressor of Ras (KSR) and potentially other serine/threonine kinases, to MEK1 a dual specificity kinase (tyrosine and serine/threonine). B-Raf is the strongest Raf kinase in terms of its ability to phosphorylate its downstream target MEK1. B-Raf has a more limited tissue distribution, but it is expressed in neuronal and some hematopoietic cells, as well as other types of cells. Finally, A-Raf is the weakest Raf kinase in terms of its ability to phosphorylate MEK1. A-Raf also has a wide tissue distribution, including hematopoietic cells. 40, 44 There is a hierarchy in the ability of the three Raf oncoproteins to transform NIH-3T3 cells with B-Raf having the greatest capacity. [45] [46] [47] Next is Raf-1 and finally A-Raf. B-Raf induced higher levels of MEK1 activity, Raf-1 moderate levels and the lowest levels of MEK1 activity were observed in A-Raf transformed cells. Many of these experiments were performed with conditional Raf oncoproteins constructed by Dr Martin McMahon (UCSF, San Francisco, CA, USA). The activated Raf oncoproteins were linked to the hormone binding domain of the human estrogen receptor (⌬Raf:ER) 46 ,47 thus the Raf oncoproteins could be turned-on by the addition of estrogen (␤-estradiol) to the growth medium. Likewise, they could be turned-off by the removal of ␤-estradiol from the growth medium. Recent experiments have used a mutant estrogen receptor domain which is activated in response to 4-hydroxytamoxifen and not ␤-estradiol.
Dr McMahon showed that the different Raf oncoproteins induced an autocrine growth factor for NIH-3T3 cells, namely heparin binding epidermal growth factor (hb-EGF). 46, 47 Raf was stimulating hb-EGF expression by modulating the activity of ETS transcription factors. 46, 47 Raf also could induce the expression of the cell cycle inhibitory protein p21
Cip-1 . High levels of Raf would induce more p21
Cip-1 protein which was correlated with cell cycle arrest. 48, 49 A-Raf, the weakest Raf oncoprotein, was a poor inducer of p21
Cip-1 . Dr McCubrey and colleagues have shown that the three Raf oncoproteins have a differential capacity to abrogate the cytokine dependency of human (TF-1) and murine (FDC-P1) hematopoietic cells when expressed from the ⌬Raf-ER constructions. Both TF-1 and FDC-P1 cell lines require either IL-3 or GM-CSF to proliferate. Removal of cytokine results in apoptosis within 1 to 3 days. Some of this work was published in the December 1998 issue of Leukemia. 40 Two different types of cells were isolated after infection with the activated Raf constructs. The majority of the cells infected with the activated Raf proteins remained cytokine-dependent for growth. A minority of the cells infected with the ⌬Raf:ER proteins grew in response to the activated Raf. This, latter class of Rafresponsive cells usually expressed higher levels of the Raf proteins and downstream MEK1 activity than the cells which remained cytokine-dependent. Interestingly A-Raf was more efficient than either Raf-1 or B-Raf in abrogating cytokine dependency of both cell lines. Studies performed by Larry Karnitz at the Mayo clinic (Rochester, MN, USA) have indicated that A-Raf, as opposed to Raf-1, may be the predominant Raf kinase, that is involved in Raf-mediated signal transduction in cytokine-dependent murine FDC-P1 cells. 28 Alternatively ARaf is a poor inducer of p21 Cipl , and there may be an intricate balance between growth promotion and cell cycle arrest promoted by the Raf oncoproteins.
Abrogation of cytokine dependency was associated with autocrine growth factor expression. Cells transformed to cytokine-independence by A-Raf produced the highest levels of autocrine GM-CSF expression. 40 The autocrine growth factor expression in the human hematopoietic cells induced by the activated Raf expression was significant as it was at sufficient levels to promote the proliferation of the parental cells. Moreover, the autocrine growth factor synthesis in the Raf-responsive cells was important as neutralizing antibodies to GM-CSF inhibited the growth of the ⌬Raf:ER-responsive cells.
Activated versions of the downstream MEK1 protein (⌬MEK1:ER) also abrogate the cytokine dependency of human and murine hematopoietic cells, although they showed a lower efficiency than either the ⌬A-Raf:ER or ⌬Raf-1:ER constructs. This lower efficiency of abrogation of cytokine dependency by ⌬MEK1:ER may be related to the position of MEK1 in the signal transduction pathway, as it may not be able to transfer its signal to as many downstream targets as Raf.
Recently there have been numerous reports suggesting interactions between Raf and apoptotic regulatory proteins. 9, 14, [18] [19] [20] [21] To determine whether Bcl-2 overexpression could synergize with activated Raf or MEK expression and increase the recovery of cytokine-dependent cells which expressed the ⌬Raf:ER or ⌬MEK1:ER oncoproteins, ⌬Raf:ER and ⌬MEK1:ER-infected cells were secondarily infected with a retrovirus encoding Bcl-2. Bcl-2 overexpression was able to synergize with activated Raf or MEK1 increasing the frequency at which cytokine-independent cells could be isolated from the cytokine-dependent ⌬Raf:ER or ⌬MEK1:ER infected cells. These cells were conditionally transformed as they required activation of either the ⌬Raf:ER or ⌬MEK1:ER proteins to proliferate. These cells in addition, displayed an altered pattern of apoptosis as it took longer for the cells to undergo apoptosis 13 upon culture in the absence of ␤-estradiol. Furthermore these Bcl-2 and ⌬Raf:ER or ⌬MEK1:ER cells were more resistant to certain drugs indicating that Bcl-2 expression could increase drug resistance.
The conditionality of the ⌬Raf:ER and ⌬MEK1:ER constructs has allowed the investigation of the downstream signal transduction pathways induced by IL-3, Raf and MEK in hematopoietic cells. In addition to the Jak/STAT pathway and the Ras/Raf/MEK/ERK pathway, IL-3 can induce the PI3K-p70S6K pathway. Dr McCubrey presented evidence indicating that both Raf and MEK1 can induce the phosphorylation of the p70S6 kinase, which lies downstream of PI3K. Thus the Raf pathway can cross-talk with other pathways which have growth promoting effects.
In addition to the Jak-STAT and Raf/MEK/ERK pathways, several alternative signal transduction cascades are activated by Ras-dependent and independent mechanisms. [50] [51] [52] Cytokines and mitogens may also activate these pathways which rely heavily on serine/threonine kinases to transduce their regulatory signals. These related pathways almost certainly interact with the Raf/MEK/ERK pathway ( Figure 1 ). Ras-dependent activation of the MEK1 kinase, MEKK1, a serine/threonine kinase, is responsible for activating three MAPK pathways. [50] [51] [52] MEKK1 phosphorylates and activates MEK1 and MEK2 53, 54 and the dual serine/threonine and tyrosine stress/extracellular regulated kinases (SEK). [54] [55] [56] [57] [58] [59] Activation of the SEKs (MKK4 and MKK3/MKK6) results in the activation of the stress activated protein kinases (SAPKs), JNK and p38 MAPK . [54] [55] [56] [57] [58] [59] JNK is a 46-kDa MAP kinase responsible for activating the AP-1 transcription factor component c-Jun by phosphorylating its serine residues 63 and 73.
58 p38 MAPK is responsible for phosphorylating and activating certain members of the AP-1 transcription factor family, the C/EBP transcription factor family member, CHOP, and the MAPK-associated protein kinase (MAPK-AP). 55, 56, 60 Activation of MEKK1 preferentially leads to the activation of JNK Ͼ p38 MAPK Ͼ ERK1 and ERK2. 55 On the other hand, Raf-1 leads to the activation of ERK1 and ERK2 but does not result in activated JNK or p38 MAPK . 61 Although pharmaceutical companies have produced specific inhibitors to p38 MAPK , direct inhibitors to JNK and ERK have not yet been developed. However, the ERKs can be indirectly inhibited using compounds such as PD98059.
Recent evidence suggests that a significant amount of crosstalk occurs among the PI3K, MEKK/SEK/SAPK and Raf/MEK/ERK pathways. [62] [63] [64] [65] [66] PI3K has been implicated in MEKK1 activation, as well as MEK1/ERK activation, [62] [63] [64] [65] [66] whereas oncogenic Raf-1 and MEK1 have also been reported to activate p70S6K in a PI3K-independent way. 66 Inhibitors of the PI3K-p70S6K pathway, Wortmannin and rapamycin, exert their effects at different points in the pathway. [67] [68] [69] [70] [71] [72] Wortmannin inhibits PI3K, while the immunosuppressive drug rapamycin inhibits p70S6K via an upstream target of rapamycin (TOR) (Figure 1 ). However, once cells have entered the cell cycle, inhibition of p70S6K does not stop proliferation. 64, 72 Use of these inhibitors has documented the PI3K-independent activation of p70S6K. 72 Rapamycin has been recognized for years as a potentially useful immunosuppressive drug. 73 Thus these inhibitors, or more likely derivatives of them, may be useful in the treatment of patients with certain leukemias.
Dr Williams also discussed some recent data concerning a Rac2 knockout mouse model. Rac2 is a member of the Rac family of GTPases, which is involved in coupling signals from membrane receptors to downstream kinase cascades. [74] [75] [76] Rac molecules can be activated by many signal transducing molLeukemia ecules including receptor-encoded tyrosine kinases, receptorassociated tyrosine kinases, hematopoietin family receptors (eg IL-3R, GM-CSF-R, erythropoietin-R), Ras or Vav guanine nucleotide exchange family members, PI3K, or other agents which induce cell stress. Rac2 is preferentially expressed in hematopoietic cells and regulates actin cytoskeleton organization. 75 Altered Rac expression may contribute significantly to neoplastic transformation, as activated forms of Rac will transform NIH-3T3 cells. 74, 75 In Rac2 knockout mice, dramatic differences in cellular adhesion and the ability of hematopoietic cells to migrate in response to chemoattractants were observed. 76 Thus disruption of this signal transduction cascade can have profound effects on the homing and chemoattractant responses of hematopoietic cells.
Protein kinase C in cytokine signaling and oncogenesis
The role of one of the neutral lipid activated kinase, PKC, in Wnt signaling and colon cancer was discussed by Dr Alan Fields (University of Texas Medical Branch, Galveston, TX, USA). An association between altered PKC expression in colon cancer has been observed. 77, 78 PKC␤ II is an upstream regulator in the Wnt signaling pathway. 78 Wnt is a cytokine related to the fibroblast growth factors and may be regulated by PKC. 78 Wnt transduces its effects through Frz, Dsh, PKC␤ II , APC and ␤-catenin. Normally PKC␤ II keeps ␤-catenin in low levels. However, in PKC␤ II -transgenic mice, the levels of ␤-catenin are increased. These mice have a higher incidence of colon cancer. There may also be an autocrine component to this model of colon cancer as one of the target genes activated by this pathway may be Wnt. This experimental model for colon cancer has relevance in human cancer, as PKC␤ II is a target of certain lipids. Thus certain diets rich in these lipids may serve to activate PKC␤ II and result in colon cancer. 79, 80 The roles of some of the other PKC isoforms in signal transduction and apoptotic pathways were discussed by Dr Allan Mufson (NCI, Bethesda, MD, USA). [81] [82] [83] [84] [85] The tyrosine kinase inhibitor genistein blocks both the IL-3 suppression of apoptosis and Bcl-2 expression. 83, 84 Moreover, D609, a specific inhibitor of phosphatidylcholine-specific phosopholipase C, also inhibits IL-3-mediated Bcl-2 expression without affecting IL-3-induced tyrosine phosphorylation. 84 Treatment of human cytokine-dependent erthroleukemic TF-1 cells with D609 induces apoptosis even in the presence of IL-3. Dr Mufson has hypothesized that these data indicate that there is a bifurcation in the signaling pathways downstream of IL-3 induced tyrosine phosphorylation. Since IL-3 and GM-CSF stimulate increases in diacylglycerol without mobilizing intracellular Ca ++ , Dr Mufson hypothesized that one of the novel Ca ++ -independent isoforms of PKC was involved in the suppression of apoptosis in IL-3/GM-CSF-dependent hematopoietic cells. To test this hypothesis, Dr Mufson transfected TF-1 cells with expression constructs containing PKC␦ or PKC⑀. 85 Overexpression of PKC⑀ in TF-1 cells had a survival effect and prevented apoptosis in TF-1 cells. In contrast, overexpression of PKC␦ did not have an anti-apoptotic effect. PKC⑀ transfectants remained viable after 72 to 96 h of cytokine deprivation, and the cells were distributed in all phases of the cell cycle, while little cellular DNA was detected in vector-alone or PKC␦-transfected cells. 85 Dr Mufson has shown that downregulation of PKC by a 24-h incubation in medium containing 100 nM phorbol-12-myristate-13-acetate (PMA) in the presence of IL-3 dramatically reduced Bcl-2 levels and induced apoptosis. 83 Rsk is a serine/threonine kinase, while CREB, Elk and Egr-1 are transcription factors. These molecules have been proposed to be regulated by the ERK molecules. GM-CSF treatment of TF-1 cells leads to activation of p90 Rsk , CREB phosphorylation and Egr-1 transcription. [86] [87] [88] [89] [90] [91] [92] The regulation of these transcription factors and kinases in response to cytokines was discussed by Dr Kathleen Sakamoto (UCLA, Los Angeles, CA, USA).
86-92 Dr Sakamoto described studies to determine the differential roles of the ERK1 and ERK2 proteins in regulation of CREB phosporylation and Egr Rsk inhibited GM-CSF induced transcriptional activation of Egr-1. In contrast, transient transfection of TF-1 cells with dominant-negative ERK1 did not inhibit GM-CSF induced transcriptional activation of Egr-1. Thus Dr Sakamoto proposed that GM-CSF induces CREB phosphorylation and Egr-1 transcription through an ERK2 but not ERK1 dependent pathway. Although the ERK1 and ERK2 molecules often appear to be coexpressed, it is now becoming apparent that they can have different biological properties.
Roles of serine phosphorylation of STAT proteins in leukemia and immunodeficiencies including AIDS
Deregulated serine/threonine phosphorylation of STAT molecules is likely involved in diverse pathological conditions and may provide a target for therapeutic intervention. The recent ability to study STAT phosphorylation in human tumors was discussed by Dr David Frank (Dana Farber Cancer Institute, Boston, MA, USA). The development of a powerful series of antibodies which specifically recognize the activated STAT proteins has allowed Dr Frank to demonstrate that in chronic lymphocytic leukemia (CLL), the most common form of leukemia in the United States, there is constitive phosphorylation of the STAT1 and STAT3 proteins on serine-727. [93] [94] [95] [96] [97] [98] [99] In contrast, MAPK (ERK1 and ERK2) are not constitutively activated in these CLL patients. These observations have clinical significance since treatment of CLL patients with fludarabine, leads to a specific loss of STAT1. Fludarabine, a purine analogue, is to date the most effective chemotherapeutic agent against CLL. 100 Fludarabine inhibits IFN␣-induced STAT1 activation and decreases STAT1 mRNA levels. Eighty to 90% of CLL patients respond to fludarabine, but the response is not prolonged and the treatment must be repeated. Furthermore, the loss of STAT1 in CLL patients undergoing fludarabine treatment likely results in severe immunodeficiencies as seen in STAT-1 deficient mice. Thus there are significant roles of STAT1 in the etiology and potential treatment of certain human leukemias. Identification of the kinases, which phosphorylate STAT1 and the downstream targets of STAT1 will increase our understanding, and may improve the treatment of CLL and other diseases.
Dr Robert Kirken (MD Anderson Cancer Center, Houston, TX, USA) discussed the roles of the STAT and JAK proteins in immunodeficiencies. By creating a series of knockout mice, the roles of the JAK and STAT proteins in immunodeficiencies are beginning to be elucidated. [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] Absence of STAT5a and STAT5b can result in a loss of the ability of certain hematopoietic cells to proliferate in response to certain cytokines. 105, 106 Moreover reduced levels of STAT5a have been detected in the spleens and lymph nodes of tumor-challenged mice. Thus STAT5a may have a significant role in tumor induced immunosuppression. 112 In hematopoietic cells isolated from HIV-infected individuals, the levels of mRNA encoding STAT5a are not affected, but the levels of STAT5a protein are decreased. 113 It is likely that HIV-1 infection alters a post-transcriptional mechanism regulating STAT5a protein levels. Thus part of the immunodeficiency observed in AIDS patients may be due to decreased levels and activities of this STAT protein.
Dr Kirken has investigated the regulation of STAT5a serine/threonine phosphorylation in a variety of cells. [114] [115] [116] Unlike other STAT proteins, STAT5a does not contain a classical MAPK recognition sequence, and is not phosphorylated by this kinase. Thus, the serine/threonine kinase, which phosphorylates STAT5a, remains unknown. The roles of STAT5a phosphorylation in hematopoietic signal transduction are being further investigated using phospho-STAT specific antibodies and 'in-gel' kinase assays.
Regulatory proteins which recognize and bind serine threonine phosphorylated proteins-potential for intervention with chemotherapeutic drugs
Some of the proteins involved in signal transduction which recognize and bind the serine/threonine phosphorylated proteins have been isolated and characterized. [117] [118] [119] [120] [121] [122] Dr Kun Ping Lu (Harvard University, Boston, MA, USA) described techniques to isolate the Pin genes encoding these proteins and discussed how these low molecular weight proteins belong to a large multi-gene family. Pin proteins are peptidyl-prolyl cis/trans isomerases (PPIase). The Pin1 protein catalyzes the isomerization of phosphorylated Ser/Thr-Pro motifs, which are present on key mitosis-specific phosphoproteins. These proteins can inhibit entry into mitosis but are required for cell cycle progression. Pin1 interacts with a subset of mitotic proteins, which include Cdc25, Myt1, Wee1, Plk1 and Cdc27. This group of proteins is also recognized by the mitosis-specific monoclonal antibody MPM-2. The activities of the Pin1 protein are specific to Ser/Thr-Pro motifs as neither phosphorylated tyrosine or glutamic acid are able to affect the prolyl isomerization. The activities of the Pin1 protein are specific to Ser/Thr-Pro motifs as neither phosphorylated tyrosine or glutamic acid are able to affect the prolyl isomerization. Dr Lu isolated the Pin genes encoding these proteins and demonstrated the WW domains to be the first phosphoserine or phosphothreonine-binding modules. Protein-interacting modules play a key role in determining the specificity of signal transduction events, and protein phosphorylation is an important mechanism in modulating the assembly of specific signaling complexes. WW domains, arrays of conserved 38-40 residues, are found in a variety of proteins in cell signaling or regulation, including several proteins involved in cytokine signal transduction. It has now been demonstrated that WW domains mediate the phosphorylation-dependent protein-protein interaction by acting as phosphoserine or phosphothreonine-binding modules, with properties analogous to SH2 domains, phosphotyrosine-binding modules. Pin1 and related proteins use their WW domains to interact with a defined subset of mitosis-specific phosphoproteins which are also recognized by the mitosis-specific monoclonal antibody MPM-2. These Pin1 targets include key mitotic phosphoproteins Cdc25, Myt1, Wee1, Plk1 and Cdc27. Furthermore, Pin1 is a peptidyl-prolyl cis/trans isomerase (PPIase), which has an extremely high degree of substrate specificity.
In contrast to other prolyl isomerases, such as cyclophilins and FK506-binding proteins, Pin1 specifically isomerizes phosphorylated Ser/Thr-Pro bonds, whose reaction is normally reduced upon phosphorylation. Therefore, Pin1 binds and isomerizes mitosis-specific phosphoproteins. Importantly, inhibiting Pin1 function leads to mitotic arrest and apoptosis. Thus, a novel cell cycle regulatory mechanism has been proposed, where protein phosphorylation creates binding sites for Pin1, which can then latch on to and isomerize the phosphorylated Ser/Thr-Pro peptide bond. In turn, this may change the shape of the protein, regulating its dephosphorylation, degradation or location in the cell. This new post-phosphorylation regulatory mechanism may help the cell orchestrate the complex events of mitosis.
Dr Lu has identified and described other related proteins (Pin 2 and TRF1), which may have roles in connecting mitotic control to the chromosomal telomeric regulatory machinery. 121, 122 Dysregulation of telomere length has been associated with cancer and aging. The mechanisms by which these Pin proteins recognize the phosphorylated proteins are being investigated by biophysical techniques. This area of research may provide potential targets for chemotherapy as some prolyl cis/trans isomerases have already been demonstrated to be the targets of immunosuppressive drugs (eg cyclosporin, FK506).
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Roles of serine/threonine kinases in post-translational modifications of the anti-apoptotic protein Bcl-2
An intensely investigated area in regulation of cell growth and prevention of apoptosis is the role of serine/threonine phosphorylation of members of the Bcl-2 family of proteins. [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] For the past few years, the phosphorylation of the anti-apototic Bcl-2 and pro-apoptotic Bad proteins have been examined by many groups. Different phosphoryation events on the Bcl-2 protein may have antiapoptotic or pro-apoptotic effects. Dr W Stratford May (University of Texas Medical Branch at Galveston, TX, USA) presented evidence indicating that the serine/threonine kinase ERK2 is a staurosporine-resistant Bcl-2 kinase (see Figure 2) . Stimulation of certain hematopoietic cell lines with the growth promoting cytokine, IL-3, or the PKC activator, bryostatin, will induce the phosphorylation of Bcl-2.
127-130 These Bcl-2 phosphorylation events are anti-apoptotic in nature. Moreover, PKC is a physiological Bcl-2 kinase, Leukemia which will mediate the phosphorylation of Bcl-2 at the regulatory S70 site. [127] [128] [129] There are also additional serine sites contained in the Bcl-2 protein, however by using a series of site-directed mutants Dr May and colleagues observed that alanine substitution for serine at residue S70 represented a loss of survival function phenotype. Thus, an intact S70 site is required for the full and potent anti-apoptotic activity of Bcl-2.
Staurosporine, a potent kinase inhibitor, can induce apoptosis by inhibiting PKC-mediated phosphorylation on S70 of Bcl-2. Overexpression of Bcl-2 can inhibit the effects of staurosporine. These observations suggest that there is a staurosporine-resistant protein kinase, which also phosphorylates Bcl-2 on S70. Addition of high concentrations of staurosporine up to 1 M and the MEK1 inhibitor PD98059, led to virtual complete inhibition of agonist (bryostatin or IL-3) induced Bcl-2 phosphorylation at S70 and also additively induced apoptosis. The possibility that ERK2 was a staurosporine-resistant protein kinase was indicated by the observation that ERK2 and Bcl-2 co-localized to the mitochondria and purified, activated ERK2 can phosphorylate Bcl-2 on S70 in a PD98059-sensitive, staurosporine-insensitive manner (Figure 2 ). Furthermore the non-peptide, polyanionic pharmaceutical drug aurintricarboxylic acid, which is an activator of ERK, induced Bcl-2 phosphorylation in hematopoietic cells deprived of IL-3 in a PD98059-sensitive, staurosporine-resistant manner. Aurintricarboxylic acid will prolong cell survival when cells are cultured in the absence of exogenous growth factors (ie IL-3 and nerve growth factor (NGF). These results indicate that the serine-threonine kinase ERK2 may be a second physiological Bcl-2 kinase. Dr May's group has described a novel mechanism by which Bcl-2 can suppress staurosporine-induced apoptosis. An overview of some of the effects of serine/threonine kinases on the phosphorylation of apoptotic molecules is presented in Figure 2 .
The control of apoptosis is a favored target of many therapeutic regimes. Thus, many investigators have sought to identify drugs, which may modulate Bcl-2 activity. [134] [135] [136] [137] [138] [139] [140] It has been shown for some time now that chemotherapeutic microtubule destabilizing drugs such as paclitaxel, vincristine, vinblastin and dolastatin as well as other anti-microtubule agents including colchicine, colcemid and podophyllotoxin trigger Bcl-2 phosphorylation in certain cells. [132] [133] [134] [135] [136] [137] [138] [139] [140] Here, however Bcl-2 phosphorylation differs from that induced by growth factors. First, drug-induced phosphorylation is temporally slow, requiring at least 2 h to visualize as compared with IL-3. Secondly, phosphorylation is associated with a morphologically distinct form of Bcl-2 not observed following IL-3 or other growth factor treatment of cells. The Bcl-2 phosphorylation events associated with these drugs are correlated with cell death. Whether paclitaxel-induced phosphorylatation of Bcl-2 inactivates Bcl-2's anti-apoptotic activity or is a 'marker' of cell death is not yet clear. Moreover, other Bcl-2 family members (Bcl-X L , A1) may also be phosphorylated in response to treatment with paclitaxel, although it should be noted that Bcl-X L does not appear to be phosphorylated in all cell types.
Dr Subrata Haldar (Case Western Reserve University, Cleveland, OH, USA) discussed the effects of paclitaxel and other drugs on Bcl-2 phosphorylation. Paclitaxel and dolastatin, can trigger Bcl-2 phosphorylation in LnCaP and PC-3 prostate cancer cells, the MCF-7 breast cancer line, as well as other cell types. [135] [136] [137] Interestingly, endogenous Bcl-2 phosphorylation has not been detected in follicular lymphoma cells-the type of cells from which the original Bcl-2-IgH translocation was originally identified. However, since active protein phospha-
Figure 2
Different effects of Bcl-2 phosphorylation on apoptosis. The effects of Bcl-2 phosphorylation induced by cytokines and microtubule destabilizing drugs are shown. Inactive NF-AT is shown in black, active NF-AT is shown in blue. A red 'P' in a white circle indicates phosphorylated serine/threonine residues on proteins. A white 'P' with a black circle surrounding it indicates phosphorylation events induced by the microtubule destabilizing drugs. Skull and cross bones indicates that apoptosis is induced. Skull and cross bones with a red 'X' through it indicates that apoptosis is prevented. tase 2A (PP2A) is directly associated with Bcl-2, 129 in order to dynamically regulate the protein, an increased level of PP2 activity, may explain why phosphorylation has not been experimentally observed in these cells. To provide a mechanistic basis for the effect of paclitaxel-induced phosphorylation, Dr Haldar has demonstrated that the mutation of S70 to alanine could not completely abrogate paclitaxel-induced Bcl-2 phosphorylation 138 and that the S87 site in Bcl-2 is also necessary for the events induced by these drugs. 139 In normal cell cycle progression, Bcl-2 becomes serine/threonine phosphorylated during the G 2 to M phase transition, the transition phase during which microtubule destabilizing drugs are active. In response to treatment with paclitaxel, cells become arrested in the G 2 /M transition. Upon treatment of CLL cells with 5 M paclitaxel, there is a prevention of Bcl-2 phosphorylation, and the cells do not progress to the G 2 /M transition. In addition, certain retinoids will also block this phosphorylation as they induce a cell cycle block at the G 2 /M transition. Human CLL cells that overexpress Bcl-2, show increased survival and are blocked at G 0 /G 1 . Treatment of non-cycling CLL cells with paclitaxel or taxotere could not result in Bcl-2 phosphorylation. In addition, in the presence of the protein synthesis inhibitor cycloheximide, paclitaxel induced Bcl-2 phosphorylation was undetectable. Flow cytometry analysis indicated a significant reduction in the G 2 /M population due to inhibition of protein synthesis. This observation reinstates the requirement of the cells to be cycling to achieve Bcl-2 phosphorylation. However, all-trans retinoic acid (ATRA) has also been shown to induce Bcl-2 phosphorylation in a pattern different from that of paclitaxel, and ATRA will induced differentiation of cells suggesting a survival role for Bcl-2 phosphorylation by retinoids in myeloid leukemia cells. 134 As mentioned earlier by Dr May, there may be several sites of serine phosphorylation on the Bcl-2 protein. Okadaic acid, a chemical that inhibits PP2A, as well as other phosphatases, stabilizes Bcl-2 phophorylation. Dr Haldar and others have hypothesized that Bcl-2 might be under tight regulation by a phosphatase. 135 Treatment of prostate cancer cells that express exogenous Bcl-2 with paclitaxel induces Bcl-2 phosphorylation and apoptosis. In contrast, treatment of the prostate cancer cells, that do not express Bcl-2, with paclitaxel does not result in apoptosis. It is possible to block Bcl-2 phosphorylation by making various site-directed mutants at Bcl-2 residues phosphorylated by treatment with paclitaxel and other chemother-
Figure 3
Interactions between serine/threonine kinases and apoptotic components-potential sites of interaction by chemotherapeutic drugs. The sites of interaction of the anti-cancer microtubule destabilizing drugs and other potential inhibitors are shown in yellow jagged circles. Some potential inhibitors include the purine analogue fludarabine, the tyrosine kinase inhibitor genistein, the PKC/serine/threonine kinase inhibitor staurosporine, Raf inhibitors, the MEK inhibitor PD98059 and the phospholipase C inhibitor D609. Also the sites of interaction of the immunosuppressive drugs CsA and FK506 are shown. Moreover, certain antibodies such as antibodies to Fas may inhibit the effects of apoptosis inducing agents. Potential stimulators of some of the enzymes are shown in red. These include bryostatin, a PKC activator and aurintricarboxylic acid, an ERK2 activator. A red 'P' in a white circle indicates phosphorylated serine/threonine residues on proteins. A black 'P' in a white circle indicates phosphorylated tyrosine residues. apeutic drugs. Dr Haldar presented evidence that there may be additional kinases other than ERK2 which phosphorylate Bcl-2 in response to paclitaxel on serines 70 and 87. 136, 137 These kinases may phosphorylate Bcl-2 in response to paclitaxel on sites, which are different from the conventional ERK2 recognition sequence. ERK2 was shown to phosphorylate both the wild-type and mutated Bcl-2 proteins, indicating that ERK2 may not be the kinase responsible for these paclitaxel-induced Bcl-2 phosphorylations. Indeed protein kinase A (PKA) was found to be able to phosphorylate Bcl-2 in vitro and to be activated by taxotere in vivo in association with Bcl-2 phosphorylation. 140 Instead, Dr Haldar presented evidence that there may be some involvement of the SAPK pathway in paclitaxel-induced phosphorylation and that this phosphorylation of Bcl-2 requires the Bcl-2 homology region-4 (BH4) domain. The experiments employing SEK-dominant negative cell lines are in progress in Dr Haldar's laboratory. Alternatively, one cannot exclude the possibility of the involvement of a 46 kDa kinase with sequence similarity to SAPK in paclitaxel-induced Bcl-2 phosphorylation.
Leukemia
The effects of Bcl-2 on drug resistance were discussed by Dr Rakesh Srivastava (National Institute on Aging, NIH, Baltimore, MD, USA). Paclitaxel and other drugs, which disturb microtubule dynamics, kill cells in a Fas/FasL dependent manner. 140, 141 Antibodies to FasL inhibit paclitaxel-induced apoptosis. Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced production of FasL and blocks paclitaxel-induced apoptosis in spite of paclitaxelinduced Bcl-2 phosphorylation. 140, 141 In addition, Bcl-2 overexpression inhibits paclitaxel-induced apoptosis by blocking the nuclear translocation of nuclear factor of activated T cells (NF-AT) by binding and sequestering calcineurin, a critical phosphatase necessary to dephophorylate NF-AT allowing NF-AT to migrate into the nucleus (Figure 2) . The BH4 domain of Bcl-2 is required for the interaction with calcineurin. In the absence of NF-AT in the nucleus, the FasL gene is not transcribed and apoptosis does not occur. Thus paclitaxel and other drugs that disturb microtubule function may kill cells in part through the induction of FasL. Once Bcl-2 is phosphorylated, it can not bind calcineurin.
Dr Srivastava has also shown that paxitaxel and vincristine induced increased expression of the pro-apoptotic Bax protein in MCF-7 and MDA-MB-23 breast cancer cells. Overexpression of Bcl-2 in these cells counteracted the effects of low doses of these drugs. Paclitaxel and vincristine-induced activation of cyclic AMP-dependent PKA induced Bcl-2 hyperphosphorylation and apoptosis. Inhibition of PKA activity blocked these events. Dr Srivastava's results suggested that PKA activation in response to microtubule damage is an important event in Bcl-2 hyperphosphorylation. In contrast, DNA damaging drugs such as methotrexate and doxorubicin had no effects on Bcl-2 hyperphosphorylation but still induced cell death. Thus Bcl-2 is not required for induction of apoptosis. Paclitaxel and vincristine induce activation of caspase 3 and cleavage of poly ADP-ribose. Both of these events are downstream of Bcl-2 phosphorylation. Dr Srivastava's work has suggested that there may be agents that disrupt or damage the cytoskeleton that are p53-independent and function through serine/threonine kinase activation. The role of paclitaxel-induced Bcl-2 phosphorylation is not yet resolved. Certain Bcl-2 phosphorylation events stimulated by growth factors (IL-3, NGF and Epo) and PKC agonists prevent apoptosis whereas other Bcl-2 phosphorylation events, and in some cases on the same serine residues, are associated with apoptosis. Whether these phosphorylation events can alter the conformation and/or the subceullular distribution of the Bcl-2 protein remains to be determined. Furthermore, the roles of phosphorylation of other Bcl-2 family members (Bcl-X L , A1, M1 and others) remain to be elucidated.
Summary
It is now clear that cytokines use multiple, overlapping pathways to stimulate and regulate cell growth and differentiation. This meeting summarized some of the roles that serine/threonine kinases have in signal transduction and the prevention of apoptosis. Clearly cytokine receptors use both tyrosine and serine/threonine kinases as well as other signal transducing molecules to activate downstream kinases, transcription factors and anti-apoptotic molecules. As these complex, interconnected pathways become unraveled, hopefully the ability to isolate chemotherapeutic drugs, which can differentially kill tumorigenic as opposed to normal cells, will be achieved. A diagram showing some of the sites of known chemotherapeutic drugs is presented in Figure 3 . Once the roles of serine/threonine kinases are elucidated, the next big step will be to determine how they are abnormally expressed in neoplasia and whether chemotherapeutic strategies can be developed to utilize these kinases as molecular targets.
